JP2021519790A5 - - Google Patents

Info

Publication number
JP2021519790A5
JP2021519790A5 JP2020553476A JP2020553476A JP2021519790A5 JP 2021519790 A5 JP2021519790 A5 JP 2021519790A5 JP 2020553476 A JP2020553476 A JP 2020553476A JP 2020553476 A JP2020553476 A JP 2020553476A JP 2021519790 A5 JP2021519790 A5 JP 2021519790A5
Authority
JP
Japan
Prior art keywords
composition
erenumab
variant
amount
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020553476A
Other languages
English (en)
Japanese (ja)
Other versions
JP7840636B2 (ja
JP2021519790A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/025223 external-priority patent/WO2019195185A1/en
Publication of JP2021519790A publication Critical patent/JP2021519790A/ja
Publication of JP2021519790A5 publication Critical patent/JP2021519790A5/ja
Priority to JP2023076664A priority Critical patent/JP2023103323A/ja
Priority to JP2025247999A priority patent/JP2026034591A/ja
Application granted granted Critical
Publication of JP7840636B2 publication Critical patent/JP7840636B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020553476A 2018-04-02 2019-04-01 エレヌマブ組成物及びその使用 Active JP7840636B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023076664A JP2023103323A (ja) 2018-04-02 2023-05-08 エレヌマブ組成物及びその使用
JP2025247999A JP2026034591A (ja) 2018-04-02 2025-12-12 エレヌマブ組成物及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862651651P 2018-04-02 2018-04-02
US62/651,651 2018-04-02
PCT/US2019/025223 WO2019195185A1 (en) 2018-04-02 2019-04-01 Erenumab compositions and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023076664A Division JP2023103323A (ja) 2018-04-02 2023-05-08 エレヌマブ組成物及びその使用

Publications (3)

Publication Number Publication Date
JP2021519790A JP2021519790A (ja) 2021-08-12
JP2021519790A5 true JP2021519790A5 (cg-RX-API-DMAC7.html) 2022-04-07
JP7840636B2 JP7840636B2 (ja) 2026-04-06

Family

ID=66248665

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020553476A Active JP7840636B2 (ja) 2018-04-02 2019-04-01 エレヌマブ組成物及びその使用
JP2023076664A Withdrawn JP2023103323A (ja) 2018-04-02 2023-05-08 エレヌマブ組成物及びその使用
JP2025247999A Pending JP2026034591A (ja) 2018-04-02 2025-12-12 エレヌマブ組成物及びその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023076664A Withdrawn JP2023103323A (ja) 2018-04-02 2023-05-08 エレヌマブ組成物及びその使用
JP2025247999A Pending JP2026034591A (ja) 2018-04-02 2025-12-12 エレヌマブ組成物及びその使用

Country Status (19)

Country Link
US (2) US11407838B2 (cg-RX-API-DMAC7.html)
EP (1) EP3774881A1 (cg-RX-API-DMAC7.html)
JP (3) JP7840636B2 (cg-RX-API-DMAC7.html)
KR (2) KR20260109951A (cg-RX-API-DMAC7.html)
CN (1) CN111954678A (cg-RX-API-DMAC7.html)
AR (1) AR114722A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019246983B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020019882A2 (cg-RX-API-DMAC7.html)
CA (1) CA3095899A1 (cg-RX-API-DMAC7.html)
CL (2) CL2020002519A1 (cg-RX-API-DMAC7.html)
EA (1) EA202092335A1 (cg-RX-API-DMAC7.html)
IL (1) IL277663A (cg-RX-API-DMAC7.html)
MA (1) MA52202A (cg-RX-API-DMAC7.html)
MX (2) MX2020010320A (cg-RX-API-DMAC7.html)
PH (1) PH12020551618A1 (cg-RX-API-DMAC7.html)
SA (1) SA520420261B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202009629YA (cg-RX-API-DMAC7.html)
TW (1) TWI847980B (cg-RX-API-DMAC7.html)
WO (1) WO2019195185A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
US11598756B2 (en) * 2020-01-30 2023-03-07 Regeneron Pharmaceuticals, Inc. Platform for native liquid chromatography-mass spectrometry
US20240209115A1 (en) * 2021-04-29 2024-06-27 Amgen Inc. Methods for reducing low molecular weight species of recombinantly-produced proteins
WO2023120561A1 (ja) * 2021-12-22 2023-06-29 中外製薬株式会社 生物活性が低下した抗体バリアント
CN115819589B (zh) * 2022-10-19 2026-06-19 武汉人福创新药物研发中心有限公司 一种培养基及生产抗cgrpr抗体的方法

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
WO1990003430A1 (en) 1988-09-23 1990-04-05 Cetus Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
AU673347B2 (en) 1992-03-17 1996-11-07 Novartis Ag Genetically engineered antibodies
DE69433747D1 (de) 1994-08-16 2004-06-03 Human Genome Sciences Inc Calcitoninrezeptor
US5785682A (en) 1995-03-22 1998-07-28 Abbott Laboratories Pre-filled syringe drug delivery system
WO1998003534A1 (en) 1996-07-23 1998-01-29 Smithkline Beecham Corporation Calcitonin gene-related peptide receptor component factor (houdc44)
US6255455B1 (en) 1996-10-11 2001-07-03 The Trustees Of The University Of Pennsylvania Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
ATE370961T1 (de) 1998-05-06 2007-09-15 Genentech Inc Reinigung von antikörpern durch ionenaustauschchromatographie
ES2228052T3 (es) 1998-06-01 2005-04-01 Genentech, Inc. Separacion demonomeros de anticuerpos de sus multimeros utilizando cromatografia de intercambio de iones.
FR2821080B1 (fr) 2001-02-20 2003-12-19 Sanofi Synthelabo Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques
DE60234944D1 (de) 2001-09-27 2010-02-11 Merck & Co Inc Isolierte dna-moleküle, die für einen humanisierten calcitonin gene-related peptide receptor kodiered assayverfahren
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20040110170A1 (en) 2002-05-18 2004-06-10 The Regents Of The University Of California Cloning and characterization of calcitonin gene related peptide receptors
MXPA05001649A (es) 2002-08-12 2005-05-27 Birkir Sveinsson Uso de compuestos antagonistas del cgrp para tratamiento de la psoriasis.
US20040176577A1 (en) 2002-09-10 2004-09-09 Eva Rojer Immunoassays for specific determination of SCCA isoforms
WO2004097421A2 (en) 2003-04-29 2004-11-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with calcitonin receptor-like receptor (calcrl)
KR20140011431A (ko) 2004-02-11 2014-01-28 아밀린 파마슈티칼스, 엘엘씨. 선택가능한 특성을 갖는 하이브리드 폴리펩티드
AU2005310305A1 (en) 2004-10-22 2006-06-08 Amgen Inc. Methods for refolding polypeptides
EP1805320B1 (en) 2004-10-22 2014-09-03 Amgen Inc. Methods for refolding of recombinant antibodies
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
ZA200705695B (en) 2004-12-21 2009-02-25 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
EP1900374B1 (en) 2005-06-16 2014-03-12 Takayuki Shindo Angiogenetic agent containing adrenomedulin as the active ingredient
GB0521139D0 (en) 2005-10-18 2005-11-23 Univ Sheffield Therapeutic agent
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
SI3045182T1 (en) 2005-11-14 2018-08-31 Teva Pharmaceuticals International Gmbh An antibody to a peptide-associated peptide antagonist to calcitonin for treating a headache in aggregates
WO2007076336A1 (en) 2005-12-22 2007-07-05 Eli Lilly And Company Treatment of migraine with anti-cgrp antibodies
WO2008112004A2 (en) 2006-08-03 2008-09-18 Astrazeneca Ab ANTIBODIES DIRECTED TO αVβ6 AND USES THEREOF
GB0708002D0 (en) 2007-04-25 2007-06-06 Univ Sheffield Antibodies
MX2010009724A (es) 2008-03-04 2010-09-28 Pfizer Ltd Procedimientos de tratamiento del dolor inflamatorio-.
FR2934597B1 (fr) 2008-07-31 2013-04-19 Univ Aix Marseille Ii Anticorps se liant aux recepteurs de l'adrenomedulline et leurs utilisations comme medicament.
CA2737045C (en) 2008-11-20 2017-11-14 Bruce Kabakoff Therapeutic protein formulations
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
PE20120359A1 (es) * 2009-03-06 2012-04-13 Genentech Inc Formulacion con anticuerpo
JP5540095B2 (ja) * 2009-07-24 2014-07-02 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 抗体製造の最適化
BR112012004464B8 (pt) 2009-08-28 2021-05-25 Labrys Biologics Inc uso de um anticorpo antagonista anti-cgrp para preparar uma composição farmacêutica para tratar e/ou prevenir dor visceral e/ou um ou mais sintomas de dor visceral, em que a dor visceral está associada á cistite intersticial (ic), e dita composição farmacêutica
BR112012014937B1 (pt) 2009-12-18 2021-01-19 Novartis Ag método de produção de um anticorpo, fragmento de anticorpo ou proteína de fusão fc purificada usando uma matriz de cromatografia de afinidade
JOP20190250A1 (ar) 2010-07-14 2017-06-16 Regeneron Pharma صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
CN108014334B (zh) 2011-05-20 2021-11-30 H.伦德贝克公司 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途
JP6292718B2 (ja) 2011-07-01 2018-03-14 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 凝集ポリペプチドから単量体ポリペプチドを分離するための方法
CA2857194A1 (en) 2011-12-07 2013-06-13 Thomas M. Dillon Igg2 disulfide isoform separation
EP2791176B1 (en) 2011-12-15 2018-07-11 Prestige Biopharma Pte. Ltd. A method of antibody purification
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
KR102215405B1 (ko) 2013-03-15 2021-02-10 암젠 인크 인간 pac1 항체
TWI596107B (zh) * 2013-06-25 2017-08-21 卡地拉保健有限公司 單株抗體之新穎純化方法
KR102251127B1 (ko) * 2013-07-12 2021-05-11 제넨테크, 인크. 이온 교환 크로마토그래피 입력 최적화의 설명
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
MX378344B (es) 2014-03-21 2025-03-10 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
UY36302A (es) 2014-09-15 2016-04-29 Amgen Inc Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp/receptor pac1 y usos de las mismas
TWI728953B (zh) 2015-04-24 2021-06-01 美商安美基公司 治療或預防偏頭痛之方法
AR104847A1 (es) 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp

Similar Documents

Publication Publication Date Title
US20240415917A1 (en) Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates
US20250228946A1 (en) Anti-cd3 antibody formulations
EP3912639A1 (en) Pharmaceutical formulations of tnf-alpha antibodies
CN108367072A (zh) 含抗-pd-1抗体avelumab的水性药物制剂
KR102754055B1 (ko) 항-her2 항체 약물 접합체 약학 제제
CN107257692A (zh) Il‑17抗体的药物产品和稳定液体组合物
CA3173919A1 (en) Use of a multimeric anti-dr5 binding molecule in combination with a cancer therapy for treating cancer
WO2011028962A1 (en) Antibody coformulations
JP2020528424A (ja) Il−15タンパク質複合体医薬組成物およびその使用
JP2011506436A (ja) 細胞傷害性tリンパ球抗原4(ctla4)に対する抗体と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法
JP7587507B2 (ja) 製剤
JP2013515049A5 (cg-RX-API-DMAC7.html)
WO2026011751A1 (zh) 抗体制剂
KR20210079373A (ko) 단백질을 포함하는 안정한 액상 조성물
WO2026067668A1 (zh) 抗il-17抗体制剂及其制备方法和应用
CN121001740A (zh) 一种复方制剂及其应用
JP2023501155A (ja) クリザンリズマブ含有抗体製剤
CN120586040A (zh) 一种抗nkg2a抗体组合物及其应用
HK40014854A (en) Dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates
HK40011182B (en) Anti-cd3 antibody formulations
HK40011182A (en) Anti-cd3 antibody formulations